Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rank in Stocks #36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
-79.71%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)

Category

Healthcare
Stock split history for Eiger BioPharmaceuticals, Inc. (EIGR)
Eiger BioPharmaceuticals, Inc. stock (symbol: EIGR) underwent a total of 2 stock splits.
The most recent stock split occurred on Jan 08, 2024.
One EIGR share bought prior to Mar 23, 2016 would equal to 0.0022222222222222 EIGR shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2024-01-08 1:30 x0.033333333333333 x0.0022222222222222
2016-03-23 1:15 x0.066666666666667 x0.066666666666667
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL